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Sildenafil, a cyclic GMP phosphodiesterase
inhibitor, induces microglial modulation
after focal ischemia in the neonatal mouse
brain
Raffaella Moretti1,2, Pierre-Louis Leger1,3, Valérie C. Besson1,4, Zsolt Csaba1, Julien Pansiot1, Lorena Di Criscio1,
Andrea Gentili1, Luigi Titomanlio1,7, Philippe Bonnin5,6, Olivier Baud1,8 and Christiane Charriaut-Marlangue1,9*
Abstract
Background: Perinatal ischemic stroke is the most frequent form of cerebral infarction in neonates; however,
evidence-based treatments are currently lacking. We have previously demonstrated a beneficial effect of sildenafil
citrate, a PDE-5 inhibitor, on stroke lesion size in neonatal rat pups. The present study investigated the effects of
sildenafil in a neonatal mouse stroke model on (1) hemodynamic changes and (2) regulation of astrocyte/microglia-
mediated neuroinflammation.
Methods: Ischemia was induced in C57Bl/6 mice on postnatal (P) day 9 by permanent middle cerebral artery
occlusion (pMCAo), and followed by either PBS or sildenafil intraperitoneal (i.p.) injections. Blood flow (BF) velocities
were measured by ultrasound imaging with sequential Doppler recordings and laser speckle contrast imaging.
Animals were euthanized, and brain tissues were obtained at 72 h or 8 days after pMCAo. Expression of M1- and
M2-like microglia/macrophage markers were analyzed.
Results: Although sildenafil (10 mg/kg) treatment potently increased cGMP concentrations, it did not influence
early collateral recruitment nor did it reduce mean infarct volumes 72 h after pMCAo. Nevertheless, it provided a
significant dose-dependent reduction of mean lesion extent 8 days after pMCAo. Suggesting a mechanism
involving modulation of the inflammatory response, sildenafil significantly decreased microglial density at 72 h and
8 days after pMCAo. Gene expression profiles indicated that sildenafil treatment also modulates M1- (ptgs2, CD32
and CD86) and M2-like (CD206, Arg-1 and Lgals3) microglia/macrophages in the late phase after pMCAo.
Accordingly, the number of COX-2+ microglia/macrophages significantly increased in the penumbra at 72 h after
pMCAo but was significantly decreased 8 days after ischemia in sildenafil-treated animals.
Conclusions: Our findings argue that anti-inflammatory effects of sildenafil may provide protection against lesion
extension in the late phase after pMCAo in neonatal mice. We propose that sildenafil treatment could represent a
potential strategy for neonatal ischemic stroke treatment/recovery.
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Background
Perinatal/neonatal arterial stroke is a cerebrovascular
event occurring around the time of birth, with patho-
logical or radiological evidence of focal arterial infarction
mainly affecting the middle cerebral arterial territory,
with an incidence of 1/2800 to 1/5000 live births. There
is currently no evidence-based treatment for neonates
with stroke [1].
Decreased regional cerebral blood flow (CBF) is the
principal factor determining the topography of tissue in-
jury after cerebral ischemia and/or hypoxia-ischemia
(HI) in the mature and immature rodents [2]. Partially
maintained blood flow in the penumbral tissue after
stroke is primarily due to the recruitment of collateral
circulation in the brain. Collateral recruitment involves
nitric oxide (NO)-dependent vasodilatation, and the
effects of endogenous NO may be enhanced by pre-
venting cGMP degradation by phosphodiesterases
(PDEs). In particular, sildenafil and tadalafil, two po-
tent selective PDE-5 inhibitors, prolong the action of
cGMP in multiple vascular territories [3]. Interest-
ingly, sildenafil treatment, by increasing CBF, reduced
HI damage in the P7 rat brain [4]. Sildenafil has been
reported to promote neurorestoration in rat models
of stroke as measured by neurogenesis, synaptogene-
sis, and angiogenesis [5] and to reduce proliferation
of astrocytes and microglia in chronic inflammatory
diseases [6].
While microglia are considered as conductors of the
inflammatory response in the central nervous system
(CNS), their contribution to the progression of ischemic
stroke remains debated [7]. Microglia/macrophages may
transition between inflammatory and healing phenotypes
in response to specific activation cues (review in [8]).
While the M1 or classic phenotype is neuroinflamma-
tory and neurotoxic, the M2 phenotype supports the re-
covery or neural tissue and is characterized by the
production of anti-inflammatory mediators and neuro-
trophic factors [9]. Although the action of sildenafil on
neuroinflammation is not fully understood, the cGMP-
PDE inhibitor zaprinast was shown to significantly re-
duce the inflammatory response of astrocytes and micro-
glia/macrophages in adult rats submitted to focal
traumatic brain injury [10].
Revealing molecular mechanisms and pharmacological
treatments that promote the transition of microglia/
macrophages towards a phenotype that facilitates the re-
pair of the neonatal brain after ischemic damage is of
therapeutic interest. The goal of this study is to examine
if sildenafil citrate (1) mediates CBF and reduces lesion
damage and (2) modifies the modulation of microglia/
macrophage between M1 and M2 phenotypes in P9 mice
subjected to ischemia after permanent middle cerebral
artery occlusion (pMCAo).
Methods
Ethics statement
All experiments were carried out (license A75-19-01,
French Department of Agriculture) in accordance with
the European Committee’s Council Directive and per-
formed to comply with the ethical guidelines of the
Robert Debre Hospital Research Council Review Board
and have been approved by the local ethic committee
(Paris7, France).
Ischemia
pMCAo was carried out under isoflurane anesthesia in
30 % O2 and 70 % N2O in P9 C57Bl/6 mouse (Janvier,
Le Genest-St. Isle, France; 4.6 ± 0.6 g, n = 148). Pups
were sacrificed at 72 h and/or 8 days after pMCAo. Two
investigators, both blinded to the treatment group, de-
termined the size of the lesion in each animal [11].
Drug treatment
In the first set of experiments, animals were randomly
divided into five groups and treated with either PBS or
a single dose of sildenafil citrate (0.5, 2.5, 10, and
15 mg/kg; Pfizer, France), given intraperitoneally (i.p.)
5 min after pMCAo. In the second set of experiments,
animals were randomly divided into three groups and
treated with either PBS or a single dose of sildenafil
citrate (0.5 and 10 mg/kg, i.p.) 5 min after pMCAo
(see Additional file 1: Figure S1 for an outline of the
experimental procedure).
cGMP measurement
Competitive enzyme immunoassay (Cayman Chemical
Company, Ann Arbor, MI, USA) was used to quantify
cGMP in the forebrain, according to the manufacturer’s
instructions. Whole brains at P9 were harvested 1 and
3 h after the administration of sildenafil (0.5 and/or
10 mg/kg) and immediately frozen at −80 °C until mea-
surements were performed.
Ultrasonographic brain imaging
Thermoregulated mice (n = 6 per group) were subjected
to ultrasound measurements under inhaled isoflurane
anesthesia (0.8 % in air via a facemask) using an echo-
graph (ACUSON S3000, Siemens, Erlangen, Germany)
equipped with a 14.5-MHz linear transducer (14L5 SP)
[12]. Heart rate and time-average mean blood flow vel-
ocities (mBFVs) were measured in both intracranial ca-
rotid arteries (ICA) and the basilar trunk (BT) at
baseline and 1 h after pMCAo and PBS and sildenafil
(10 mg/kg) treatment.
Laser speckle contrast (LSC) imaging
Imaging was carried out using a full-field laser perfusion
imager (FLPI2, Moor Instruments Ltd., Axminster, UK)
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[12]. Briefly, thermoregulated and anesthetized (with 1 %
isoflurane inhalation in air via a facemask) mouse pups
(n = 6 per group) were placed in lateral decubitus and
the skin incised to provide access to the skull. Vegetable
oil was applied to avoid surface dryness. Speckle images
(760 × 568 pixels) were collected at 0.25 Hz (4 ms expos-
ure time) and recorded at baseline, after MCA electro-
coagulation and 5, 15, 60, and 90 min after treatment.
Blood fluxes were measured in three cortical regions of
interest (ROI, 50 × 50 pixels), ROI 1 present in the core
of the infarct and ROI 2 and ROI 3 in the proximal and
distal penumbra, respectively. Fluxes in the ROIs were
expressed in arbitrary units using a 16-color palette.
Real-time quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR)
Animals were sacrificed at 72 h and 8 days after pMCAo
(n = 8 per group). The harvested tissues correspond to
the parietal cortex, including the ischemic core (pale
zone) and penumbra at 72 h, and the penumbra at 8 days
as the pale zone being a cavity. Total RNA was extracted
using RNeasy lipid tissue mini kit (Qiagen, Courtaboeuf,
France). RNA purity and quality were assessed by spec-
trophotometry with the NanoDrop™ apparatus (Thermo
Scientific, Wilmington, DE, USA). Total RNA (1–2 μg)
was subjected to reverse transcription using the iScript™
cDNA synthesis kit (Bio-Rad, Marnes-la-Coquette,
France). RT-qPCR was performed in duplicates for each
sample using SYBR Green Supermix (Bio-Rad) for 40 cy-
cles with a 2-step program (5 s of denaturation at 96 °C
and 10 s of annealing at 60 °C). Amplification specificity
was assessed by melting curve analysis. Primers were de-
signed using Primer3 software. Sequences and NCBI ref-
erences are provided in Additional file 2: Table S1.
Abundance of transcripts of interest was expressed rela-
tive to the expression of the reference gene, glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH). Analyses
were performed with the Bio-Rad CFX Manager 2.1
software.
Immunohistochemistry
Coronal 16-μm thick paraffin sections at the MCA and
hippocampal level (corresponding to 3.27 and
4.83 mm—atlas of the developing mouse brain at P6)
were stained for mouse anti-GFAP (Sigma-Aldrich
G3893; 1:500 dilution), goat anti-Iba1 (Abcam ab5076;
1:500), rabbit anti-Iba1 (Wako, 019-19741; 1:1000), goat
anti-MRC1 (MMR/CD206 polyclonal Goat IgG, R&D
system, AF2535; 1:400), rabbit anti-COX-2 (Abcam;
1:200), goat anti-arginase-1 (Santa Cruz Biotechnology,
Inc., sc-18354; 1:200), rabbit anti-Glut1 (54-KDa form,
Millipore, Molsheim, France; 1:700), and tomato lectin
(Vector Laboratories, 1:500). For immunofluorescence,
secondary antibodies coupled with the green marker
Fluoroprobe S488 (Interchim, Montluçon, France) or the
red fluorescent marker cyanine 3 (Jackson Immuno
Research laboratories, West grove, PA) were used. For
confocal imaging, sections were analyzed using a Leica
TCS SP8 confocal scanning system (Leica Microsystems,
Wetzlar, Germany) equipped with 405-nm diode, 488-nm
argon, and 561-nm DPSS lasers. A series of optical sec-
tions separated by 0.3 μm was collected using the ×63 HC
PL APO CS2 objective (numerical aperture 1.40). For each
optical section, double- or triple-immunofluorescence im-
ages were acquired in sequential mode to avoid potential
contamination by fluorescence emission overlap. The or-
thogonal sectioning and 3D viewing were produced by the
Leica Application Suite X-software (Leica Microsystems).
Images were equally adjusted for brightness and contrast,
and composite illustrations were built in Adobe Photo-
shop CS3 (Adobe Systems, San Jose, CA).
Cell quantification
GFAP and Iba-1-positive cells were counted in a blind
manner in the penumbra region on three coronal sec-
tions for animal at 72 h and 8 days after ischemia
and in age-matched controls using a ×20 objective.
Iba-1-Arg-1 and Iba1-COX-2 double-positive cells
were counted in the same regions with a ×20 lens
and then merged images were created with Fiji soft-
ware (http://fiji.sc/Fiji).
Statistical analysis
Values are expressed as mean ± SD (BF measures and le-
sion volume) and mean ± SEM (RT-qPCR, immunohis-
tochemistry, and immunofluorescence). BFV and CBF
values measured in the different ROIs were compared
using repeated measures ANOVA and a post hoc
Newman-Keuls test to analyze differences between the two
groups. One-way ANOVA followed by a Newman-Keuls
post hoc test was used for the difference between two
groups (RT-qPCR, immuno-labeled cells, and lesion vol-
umes). Statistical analyses were performed using GraphPad
PRISM version 5.0 (GraphPad Software, San Diego, CA).
Results
Setup of the animal model and effect of sildenafil on CBF
and lesion size
In the first set of experiments (Additional file 1: Figure S1),
animals were assessed by color-coded pulsed Doppler ultra-
sound imaging at baseline and after pMCAo. As compared
to basal mBFV, pMCAo induced a significant transient de-
crease in mBFV in the left ICA and a consecutive signifi-
cant increase in mBFV in the basilar trunk (BT) 15 min
after pMCAo (Additional file 1: Figure S2A). One hour
after pMCAo, no significant change in mBFV was observed
in the three large arteries (data not shown). One hour after
pMCAo and sildenafil administration (10 mg/kg, n = 8
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each) mBFVs were not modified in the three large arteries
as compared to a single PBS administration (Fig. 1a). Heart
rates in the sildenafil-treated animals (395 ± 67 bpm) were
not significantly different from PBS-treated animals (428 ±
66 bpm) at this time point. No difference was observed be-
tween the different doses of sildenafil on mBFVs measured
in the large arteries (data not shown), except for the 15 mg/
kg dose (Additional file 1: Figure S2B).
Representative patterns and values of cortical BF using
LSC imaging are shown in Fig. 1b, c. Immediately after
pMCAo, BF dropped in the ROI 1 (core) to a mean
value around 40–42 % of basal BF in both groups of ani-
mals (n = 6 each) and was reduced further to 33–36 % of
basal at 90 min after pMCAo. A similar drop in BF was
measured in the ROI 2 and in a less severe manner in
the ROI 3. BF was further reduced at 90 min after
pMCAo, in particular in ROI 3. As expected, sildenafil
treatment (10 mg/kg) significantly increased the
concentration of intracellular cGMP to 1.91 ± 0.38 and
1.87 ± 0.31 pmol/mL at 1 and 3 h after administration,
respectively, as compared to PBS-treated animals (0.08
± 0.02 pmol/mL, p < 0.001) (Additional file 1: Figure S3).
No statistical difference in cGMP concentration was
found between the different doses used. Nevertheless,
sildenafil treatment did not significantly modify the BF
profile in the three distinct ROIs at any time point.
Mean cortical infarct volume at 72 h after pMCAo was
12.5 ± 3.0 % (n = 14, one animal died) in PBS-treated ani-
mals. Sildenafil at the three lower doses tested (0.5, 2.5, and
10 mg/kg) did not change the mean infarct volume (11.0 ±
3.0 %, n = 7; 12.2 ± 3.1 %, n = 8; and 13.4 ± 2.3 %, n = 7, re-
spectively, N.S.), whereas it increased both infarct volume
(21.6 ± 4.6 %, n = 7, p < 0.001, Fig. 2a) and mortality (3/10
animals died) at 15 mg/kg, suggesting toxicity at high doses
(Fig. 2a). Therefore, the 15-mg/kg dose was not further
used in the following experiments. Eight days after
Fig. 1 Redistribution of blood flow after permanent MCAo (pMCAo) in C57BL/6 P9 mice using ultrasound Doppler and laser speckle contrast
(LSC) imaging. a Variation in mean blood flow velocity (mBFV) in the large cerebral arteries (lICA left ICA, rICA right ICA, BT basilar trunk) 1 h after
pMCAo and administration of PBS and/or sildenafil (10 mg/kg; n = 6 per group). b, c Representative color-coded LSC images (b) and time-course
of cortical blood flow (c) taken in basal, upon MCAo, shortly after sildenafil treatment (Tr, PBS, and/or sildenafil, Sil, 10 mg/kg), and after 5, 15, 60,
and 90 min in three ROIs (ROI 1, core; ROI 2 and ROI 3 close and far away from the penumbra, respectively). BF is expressed in arbitrary units
(A.U.) according to the color-coded scale (0 to 1500)
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Fig. 2 Effect of sildenafil citrate on the cortical infarct volumes and tissue loss measured 72 h and 8 days after pMCAo, respectively. Sildenafil
citrate was given after pMCAo by a single intraperitoneal injection either with PBS or 0.5, 2.5, 10, and 15 mg/kg sildenafil. a Cortical lesion at 72 h.
b Tissue loss at 8 days. Horizontal bar represents the mean. Note that the 15 mg/kg dose is toxic by increasing the infarct volume. Each dot
represents one animal. Data were assessed via an ANOVA, and when significant the results of the Newman-Keuls post-test are shown, ** p < 0.01,
*** p < 0.001 sildenafil dose vs PBS
Fig. 3 Effect of sildenafil citrate on the density of microglia/macrophages cells and COX-2 expression at 72 h after pMCAo. a Quantitative analysis
of tomato-lectin (TL, n = 6–7 per group) in PBS, Sil-0.5, and Sil-10 (mg/kg)-treated animals. b–d Localization and quantification of COX-2+ cells in
the core and/or the penumbra in PBS- and sildenafil-treated animals. ** p < 0.01, ***p < 0.001, sildenafil vs PBS treatment. ##p < 0.01, ###p < 0.001,
sildenafil 0.5 vs sildenafil 10. Scale bar represents 100 μm (b) and 50 μm (enlarged panels)
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pMCAo, lesion volume significantly increased up to 23.8
± 7.5 % (n = 16, p < 0.01 vs 72 h) in PBS-treated animals
and became cystic. Sildenafil significantly counteracted
this increase in a dose-dependent manner to 16.4 ± 4.8 %
(sildenafil 0.5 mg/kg; n = 13; p < 0.01) and 11.0 ± 4.8 % (sil-
denafil 10 mg/kg; n = 13; p < 0.001) (Fig. 2b).
Effect of sildenafil treatment on glial activation
Reactive astrogliosis manifested by a significant in-
crease in GFAP immunoreactivity was clearly ob-
served around the lesion in PBS-treated animals at
72 h after pMCAo (Additional file 1: Figure S4 and
Additional file 1: Figure S5A, B). Surprisingly, sildena-
fil significantly increased the prevalence of GFAP+
cells at 10 mg/kg. Conversely, sildenafil significantly
reduced the number of GFAP+ cells 8 days after
pMCAo as compared to PBS-treated animals. No sig-
nificant difference was observed between PBS and
0.5 mg/kg sildenafil treatment at either time point
(Additional file 1: Figure S4).
A high abundance of microglia/macrophages (stained
by tomato lectin (TL)) was detected in the penumbra
(including the white matter) at 72 h. Sildenafil treatment
significantly decreased the number of TL+-cells at 10 but
not 0.5 mg/kg (Fig. 3a and Additional file 1: Figure S5C, D).
At this time point, cells positive for the M1-like marker
COX-2+ [13] were found in the ischemic core in PBS-
treated animals, whereas they were mostly observed in the
Fig. 4 Gene expression of microglia/macrophage M1-like markers in PBS- and sildenafil (Sil)-treated animals, 72 h and 8 days after pMCAo. M1
markers were measured in the ipsilateral (IL) and contralateral (CL) sides in PBS (plain bars) and sil-10 (hatched bars) animals. Data are mean ± SEM.
Data were assessed via an ANOVA, and when significant, the results of the Newman-Keuls post-test are shown; *p < 0.05, and ***p < 0.001,
compared to PBS
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Fig. 5 (See legend on next page.)
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penumbra in 10 mg/kg (but not 0.5 mg/kg) sildenafil-
treated animals (Fig. 3b–d). In contrast, 8 days after
pMCAo the number of microglia/macrophages stained by
Iba-1 were significantly reduced by sildenafil treatment (0.5
and/or 10 mg/kg dose) (Fig. 6b).
We then focused on the phenotype of microglial cells at
both transcriptional (Figs. 4 and 5) and translational
(Figs. 6 and 7) levels in the cortical tissue obtained from
PBS- and sildenafil-treated animals. Seventy-two hours
after pMCAo and PBS treatments, most of the markers
(M1- and M2-like) were increased with the exception of
ptgs2 (COX-2). As compared to PBS, sildenafil (10 mg/kg)
did not change the expression of M1-like (ptgs2, CD32
and CD86) markers 72 h after ischemia. In contrast, a sig-
nificant increase was measured for CD32 and CD86 8 days
after pMCAo (Fig. 4). At 72 h after pMCAo, sildenafil
treatment (10 mg/kg) significantly decreased mRNA ex-
pression of M2-like markers (CD206, IL1-Rn, and IL4-Ra)
but not Arg-1 and Lgals3. In contrast, most of these
markers (CD206, Arg-1, Lgals3 and IL1-Rn) were in-
creased 8 days after pMCAo (Fig. 5).
To further address the effect of sildenafil treatment on
M1 and M2 markers, we examined the co-localization of
Iba-1+ (a marker for both M1 and M2 microglia/macro-
phages) with either the M2-like marker Arg-1 (Fig. 6a,
upper panel) or the M1-like marker COX-2 (Fig. 6a,
lower panel) in the cortical penumbra. While a global
decrease of Iba-1+ microglia/macrophage was observed
by sildenafil irrespective of dosage (Fig. 6b), an increase
of Iba-1+Arg-1+ double-positive M2 microglia/macrophage
was observed at 10 but not 0.5 mg/kg (Fig. 6c), suggesting
that a high dosage of sildenafil was required for microglia/
macrophages to obtain the M2 status. Interestingly, sildena-
fil decreased the number of Iba-1+COX-2+ double-positive
M1 microglia/macrophages irrespective of dosage
(Fig. 6d), suggesting it does not only affect phenotype
polarization and that a lower dose threshold is re-
quired for inhibition of neurotoxic M1-type than for
activation of neuroprotective M2-type microglia/
macrophages.
Co-expression of M1- and M2-like markers in perivascular
microglia/macrophages
The macrophage mannose receptor MRC-1 (CD206), a
marker for M2-type microglia/macrophages, was mainly
detected in the leptomeninges from where they entered
the neocortex along the penetrating arterioles in the
penumbral tissue at 72 h (Fig. 7) and 8 days after
pMCAo (data not shown). On confocal images, we ob-
served the co-localization of MRC-1 with the M1 marker
COX-2 (Fig. 7a) indicating either a mixed phenotype or
lack of specificity of this marker. MRC-1 expression was
present in macrophages/microglia localized around micro-
vessels labeled with the endothelial marker Glut-1 (stained
with 54 kDa Glut-1 protein, which regulates import of
glucose from the blood to the brain across the endothelial
cells of the blood-brain barrier) and present in the penum-
bra (Fig. 7b and Additional file 1: Figure S6). A few COX-
2+/Arg-1+-cells (2–4 cells per brain section) were still de-
tected in the leptomeninges in both PBS- (Fig. 7c) and sil-
denafil- (10 mg/kg, data not shown) treated animals
8 days after pMCAo.
Discussion
In this study, we show that brain lesions induced by
pMCAo in P9 mouse pups evolve between 72 h and
8 days post-ischemia and that the selective inhibition of
PDE-5 by sildenafil dose-dependently reduces lesion ex-
tent at 8 days post-pMCAo. The protective action of sil-
denafil appeared to involve a reduction in the overall
number of microglia/macrophages in the late phase of
lesion development as well as their polarization towards
a neuroprotective M2 phenotype.
Whereas lesion volumes decrease after pMCAo in
adult mice between 24 h and 7 days [14], they increased
between 3 and 8 days in neonatal mice, as previously
shown in neonatal rat [15]. Whether this difference re-
flects upon continued tissue destruction even in late
phases after occlusion or reduced growth potential of
the neonatal brain is yet unclear. Sildenafil treatment re-
duced lesion size at 8 days post-pMCAO, similar to that
found at 72 h, suggesting that sildenafil prevents lesion
enlargement. We previously reported that sildenafil
treatment, associated with an early significant increase
in cerebral blood flow (CBF), reduces hypoxic-ischemic
damage in the P7 rat brain [4]. By using both US and
LSC imaging, we were here unable to observe early
hemodynamic changes in either sildenafil- or PBS-
treated mice. A high variability in the number of lepto-
meningeal and/or pial vessels may explain the
hemodynamic differences observed between the rat and
mouse. Indeed, all ischemic models in the rat combine
transient occlusion of two arteries at the same time, ei-
ther pMCAo with transient occlusion of one or both
common carotid arteries [2, 16] or blockade of the past
external carotid artery-internal carotid artery bifurcation
(See figure on previous page.)
Fig. 5 Gene expression of microglia/macrophage M2-like markers in PBS- and sildenafil (Sil)-treated animals, 72 h and 8 days after pMCAo. M2
markers were measured in the ipsilateral (IL) and contralateral (CL) side in PBS- (plain bars) and sil-10 (hatched bars) animals. Data are mean ± SEM.
Data were assessed via an ANOVA, and when significant, the results of the Newman-Keuls post-test are shown; *p < 0.05, **p < 0.01, and
***p < 0.001, compared to PBS
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[17, 18]. In contrast, a single pMCAo is sufficient to cre-
ate ischemic lesions in mice [19]. Together, this suggests
that combined occlusion of carotid and MC arteries is
necessary to drop the BF in the ipsilateral hemisphere
sufficiently for anastomoses to no longer be efficient
despite the circle of Willis and to create a lesion in the
rat. As BF was only measured up to 90 min after
pMCAo, we cannot exclude the contribution of late col-
lateral opening and patency. Together, our data suggest
that sildenafil, although given shortly after pMCAo, may
have other neuroprotective effects that may develop at
later time points of recovery.
The impact of inflammation on post-injury outcome
in the developing brain is increasingly recognized. In our
pMCAo model in the P9 mouse, strong astrocytic and
microglial responses were detected 72 h after injury and
persisted for more than 1 week (personal data). We
show that sildenafil potentiates reactive astrogliosis 72 h
after pMCAo, in agreement with a previous report fol-
lowing focal cryolesions onto the cortex in adult rats
treated with zaprinast and killed 3 days thereafter [9].
Zaprinast was expected to accelerate the formation of
the glial scar and the regeneration of the injured tissue
[10]. Sildenafil similarly increased GFAP immunoreactiv-
ity in adult mice submitted to a cortical cryolesions [20].
After brain injury, NO-dependent cGMP formation can
occur in the astrocytes following NO synthase-2 induc-
tion in activated astrocytes and infiltrating macrophages
[21, 22]. Natriuretic peptides (NPs) comprising atrial
(ANP), brain NP (BNP), and C-type (CNP) share the
Fig. 6 Effect of sildenafil on the number of Iba-1-positive microglia and M2 and M1 phenotypes 8 days after pMCAo. a Typical example of double
fluorescence labeling in the cortical penumbra for Iba-1 and Arg-1 and Iba-1 and COX-2 cells in a PBS-treated animal. Note that almost Iba-1+ cells
are co-stained with COX-2 marker (white arrows), which is not the case for double-stained Iba-1+-Arg-1+ cells. b–d Quantification of the number
of Iba-1+, Iba-1+-COX-2+, and Iba-1+-Arg-1+ microglia cells in PBS-treated and sildenafil-treated (0.5 and 10 mg/kg) animals. Data are mean ± SEM.
Data were assessed via an ANOVA, and when significant, the results of the Newman-Keuls post-test are shown. *p < 0.05, **p < 0.01, sildenafil vs
PBS treatment
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same intracellular signal transduction pathways with
cGMP/cGMP-dependent protein kinase (cGK) as well as
the NO pathway. The NPs/NO/cGMP/cGK pathway has
been reported to increase BF and to be critical for neo-
vascularization in vivo [23]. Interestingly, the content of
ANP has been reported to increase in reactive astrocytes
3 days after injury in the white matter (WM) from
autopsied human brain specimens after brain infarction
and upregulation of the ANP/cGMP pathway (ANP is a
vasorelaxant) may contribute to an increase in BF in re-
sponse to the BF reduction in the infarcted area [24].
The increase of GFAP+ cells observed here 3 days after
pMCAo might be related to an increase in ANP and
subsequent BF that we did not evaluate and could
Fig. 7 3D confocal analysis of double-labeled microglia and vessels after pMCAo and PBS and/or sildenafil (0.5 mg/kg) treatment.
a Co-localization of M1 (COX-2 in red) and M2 (MRC-1 in green) markers in the leptomeningeal membranes, 72 h after ischemia. b MRC-1 (in red)
is present in the perivascular microglia (in green). c Co-localization of M1 (COX-2 in green) and M2 (Arg-1 in red) markers in the leptomeningeal
membranes 8 days after pMCAo, in a PBS-treated animal. Scale bar represents 10 μm (a–c)
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further explain the delayed reduction in astrogliosis ob-
served at 8 days after pMCAo.
Another important finding of this study is that sildena-
fil reduces the recruitment and activation of microglia/
macrophages in the penumbral tissue at both 72 h and
8 days after pMCAo, as found for zaprinast in the cor-
tical cryolesion model [9]. Microglial activation may be
beneficial or harmful depending on polarization towards
a pro-inflammatory M1 or an anti-inflammatory and
pro-healing M2 phenotype [25]. Information regarding
the expression of M1 and M2 markers and their tem-
poral and spatial evolution in the ischemic brain are
largely lacking. Changes in mRNA expression of M1 and
M2 markers were maximally increased between 3–5 and
14 days after transient MCAo in the adult C57BL/6 mice
[26].
In our neonatal mouse model, we observed an impact
of sildenafil treatment on macrophage/microglia activa-
tion and the expression of M1- and M2-like markers.
Whereas sildenafil only increased M1-like genes 8 days
after ischemia, it decreased M2-like genes expression at
the same time point. Cyclooxygenases (COX-1 and
COX-2), which produce vasodilatory prostaglandins [27],
contribute to neurovascular coupling [28] and could
contribute to vasodilation in the penumbra and a subse-
quent absence of lesion extension in animals treated
with sildenafil. Furthermore, cerebrovascular dilations to
hypercapnia were demonstrated to be prostanoid
dependent and nitric oxide independent in the newborn
pig brain [29, 30]. The combined increase of potential
vasodilatory mediators in astrocytes and COX-2+ cells in
the penumbra at 72 h could, therefore, induce patency
and/or recruitment of collaterals leading to a reduced
damage 5 days after (at P17).
A significant upregulation of M2-like mRNA was de-
tected after sildenafil treatment. In the adult rodent, M1
markers (iNOS, CD11b, CD16, and CD32) were still ele-
vated at 14 days after stroke, while M2 markers (CD206,
Arg-1, Ym1/2 and IL-10) were decreased at 7 days after
ischemia [31]. The M2 phenotype has a stronger cap-
acity to elicit phagocytosis of dead neurons to avoid sec-
ondary inflammatory response and promote tissue
regeneration, probably by the ANP/cGMP/cKG pathway
[32]. We suggest a shift in polarization towards the M2
phenotype may contribute to the ability of sildenafil to
prevent the late-stage extension of lesions in our model.
We also found MRC-1 (CD-206) protein in infiltrating
macrophages (in the leptomeninges), as previously re-
ported after hypoxia-ischemia in the P7 rat [33]; how-
ever, we further demonstrate that MRC-1+/CD206
perivascular microglia/macrophages entered the brain
via penetrating microvessels. In contrast CD-206+ cells
were exclusively located in the ischemic core in adult
mice 24 h after pMCAo [34]. Interestingly, mixed
transitional (Mtran) phenotype has been introduced to
characterize double-labeled M1-M2 macrophage/microglia
following traumatic brain injury [35]. Such MRC-1+/COX-
2+ and Arg-1+/COX-2+ macrophage/microglia in the lepto-
meninges may also represent a transitional Mtran pheno-
type in our ischemic model.
Conclusions
In conclusion, our study suggests that sildenafil may pre-
vent the progression of the ischemic lesions in neonatal
mice through the modulation of inflammatory pathways
including microglial/macrophage polarization. Further
investigation is needed to elucidate mechanisms that
govern the change in microglia/macrophage phenotype
and the regulation of lesion size in the neonatal rodent
brain. As the use of sildenafil is indicated for idiopathic
pulmonary hypertension [36], it could be explored for
immunomodulatory stroke treatment in children.
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